Fig. 2: Responsiveness of SB-HCC to CD8-mediated immune checkpoint blockade is abolished by VSV virotherapy.
From: Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response
Animals in all arms underwent hydrodynamic injection of hMet + S45Y ß-Catenin at day 0. N = 67 animals (A–C). A–C Control IgG or anti-PD-L1 ICI therapy was initiated at day 21 for 6 doses (days 21, 23, 25, 28, 30, 31) in non-depleted mice or in mice depleted of CD8 (A), CD4 (B) or NK cells (C) as shown (8 total doses). Survival with time is shown. D Mice hydrodynamically injected with hMet + S45Y ß-Catenin at day 0 were treated with PBS or VSV-mIFNß on days 21, 23, and 25 (3 doses, 108 pfu/dose), followed by control IgG isotype or anti-PD-L1 on days 28, 30, 32, 35, 37, 39 (6 doses, 200 µg per dose). Survival with time is shown. E Mice hydrodynamically injected with hMet + S45Y ß-Catenin at day 0 were treated with control IgG isotype or anti-PD-L1 on days 21, 23, 25, 28, 30, 33 (6 doses, 200 µg per dose) and with PBS or VSV-mIFNß on days 40, 42 and 44 (3 doses, 108 pfu/dose). Survival with time is shown. Significance was determined through survival curve comparison testing using a log-rank Mantel-Cox test.
